ERCC4 and cancer: No significant association was observed between XPF Arg415Gln polymorphism and cancer risk when all the eligible studies were pooled into the meta-analysis (dominant model: OR = 1.04, 95% CI = 0.93–1.15, Ph<0.001, I2 = 62.6; recessive model: OR = 1.11, 95% CI = 0.81–1.52, Ph = 0.068, I2 = 30.5; additive model: OR = 1.05, 95% CI = 0.94–1.16, Ph<0.001, I2 = 66.7; Gln/Gln versus Arg/Arg: OR = 1.10, 95% CI = 0.79–1.54, Ph = 0.035, I2 = 35.7; Arg/Gln versus Arg/Arg: OR = 1.02, 95% CI = 0.91–1.14, Ph<0.001, I2 = 62.5).